CVA Family Office’s Alkermes ALKS Stock Holding History

CVA Family Office’s Portfolio ALKS Stock Details ALKS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$8.33K	Buy	159 +127	+397%	+$4.96K	﹤0.01%	1076
2026 Q1	$1.13K	Buy	+32	New	+$993	﹤0.01%	1631

Other funds holding ALKS

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

CVA Family Office's ALKS Position: Q2 2026 in Review

CVA Family Office increased its Alkermes (ALKS) stake by 397% in Q2 2026, buying an estimated $4.96K and bringing the position to 159 shares worth $8.33K. The position accounts for ﹤0.01% of the portfolio, ranked #1076.

CVA Family Office first reported a position in ALKS in Q1 2026 and has held it in 2 quarters since. 424 funds tracked by Wall St. Rank hold ALKS as of Q2 2026.

CVA Family Office held 159 shares of Alkermes worth $8.33K as of Q2 2026.
CVA Family Office bought 127 Alkermes shares in Q2 2026, an estimated $4.96K.
Alkermes made up ﹤0.01% of CVA Family Office's portfolio in Q2 2026, its #1076 holding.
CVA Family Office first reported a position in Alkermes in Q1 2026 and has held it in 2 quarters since.
424 funds tracked by Wall St. Rank held Alkermes as of Q2 2026.

Based on CVA Family Office's 13F filing for Q2 2026, filed 7 Aug 2026.